Intervention Review

Statins for the prevention of dementia

  1. Bernadette McGuinness1,*,
  2. David Craig1,
  3. Roger Bullock2,
  4. Peter Passmore1

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 15 APR 2009

Assessed as up-to-date: 6 NOV 2008

DOI: 10.1002/14651858.CD003160.pub2

How to Cite

McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD003160. DOI: 10.1002/14651858.CD003160.pub2.

Author Information

  1. 1

    Queen's University Belfast, Department of Geriatric Medicine, Belfast, UK

  2. 2

    Kingshill Research Centre, Victoria Hospital, Swindon, UK

*Bernadette McGuinness, Department of Geriatric Medicine, Queen's University Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast, BT9 7BL, UK. b.mcguinness@qub.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 15 APR 2009

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Timothy M. Hughes, Oscar L. Lopez, Rhobert W. Evans, M. Ilyas Kamboh, Jeff D. Williamson, William E. Klunk, Chester A. Mathis, Julie C. Price, Ann D. Cohen, Beth E. Snitz, Steven T. DeKosky, Lewis H. Kuller, Markers of cholesterol transport are associated with amyloid deposition in the brain, Neurobiology of Aging, 2014, 35, 4, 802

    CrossRef

  2. 2
    Michael Brainin, Karl Matz, Matthias Nemec, Yvonne Teuschl, Alexandra Dachenhausen, Susanne Asenbaum-Nan, Christian Bancher, Berthold Kepplinger, Stefan Oberndorfer, Michaela Pinter, Peter Schnider, Jaakko Tuomilehto, Prevention of poststroke cognitive decline: ASPIS – a multicenter, randomized, observer-blind, parallel group clinical trial to evaluate multiple lifestyle interventions – study design and baseline characteristics, International Journal of Stroke, 2014, 9, 5
  3. 3
    Christopher D. Etherton-Beer, Vascular cognitive impairment in dementia, Maturitas, 2014,

    CrossRef

  4. 4
    C. Holmes, Review: Systemic inflammation and Alzheimer's disease, Neuropathology and Applied Neurobiology, 2013, 39, 1
  5. 5
    Jean-Paul Billot, L’homéopathie ouvre de nouvelles voies de recherche dans la maladie d’Alzheimer, La Revue d'Homéopathie, 2012, 3, 3, 80

    CrossRef

  6. 6
    Gavin Tansley, Daniel T. Holmes, Dieter Lütjohann, Elizabeth Head, Cheryl L. Wellington, Sterol Lipid Metabolism in Down Syndrome Revisited: Down Syndrome Is Associated with a Selective Reduction in Serum Brassicasterol Levels, Current Gerontology and Geriatrics Research, 2012, 2012, 1

    CrossRef

  7. 7
    Robert H. Howland, Alternative Drug Therapies for Dementia, Journal of Psychosocial Nursing and Mental Health Services, 2011, 49, 5, 17

    CrossRef

  8. 8
    D. Allan Butterfield, Eugenio Barone, Cesare Mancuso, Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders, Pharmacological Research, 2011, 64, 3, 180

    CrossRef

  9. 9
    G.B. John Mancini, Steven Baker, Jean Bergeron, David Fitchett, Jiri Frohlich, Jacques Genest, Milan Gupta, Robert A. Hegele, Dominic Ng, Janet Pope, Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference, Canadian Journal of Cardiology, 2011, 27, 5, 635

    CrossRef

  10. 10
    Alex E. Roher, Suzanne L. Tyas, Chera L. Maarouf, Ian D. Daugs, Tyler A. Kokjohn, Mark R. Emmerling, Zsolt Garami, Marek Belohlavek, Marwan N. Sabbagh, Lucia I. Sue, Thomas G. Beach, Intracranial atherosclerosis as a contributing factor to Alzheimer’s disease dementia, Alzheimer's & Dementia, 2011, 7, 4, 436

    CrossRef

  11. 11
    J.M. Jordan, M.F. Sowers, S.P. Messier, J. Bradley, G. Arangio, J.N. Katz, E. Losina, L. Rovati, N. Bachtell, C. Cooper, T. Spector, W. Zhang, J. Gardiner, M. Wahba, Methodologic issues in clinical trials for prevention or risk reduction in osteoarthritis, Osteoarthritis and Cartilage, 2011, 19, 5, 500

    CrossRef

  12. 12
    Leon Flicker, Cardiovascular Risk Factors, Cerebrovascular Disease Burden, and Healthy Brain Aging, Clinics in Geriatric Medicine, 2010, 26, 1, 17

    CrossRef

  13. 13
    Sanjeev M. Kamat, Anjali S. Kamat, George T. Grossberg, Dementia Risk Prediction: Are We There Yet?, Clinics in Geriatric Medicine, 2010, 26, 1, 113

    CrossRef

  14. 14
    David D. Waters, Exploring new indications for statins beyond atherosclerosis: Successes and setbacks, Journal of Cardiology, 2010, 55, 2, 155

    CrossRef

  15. 15
    Javier Gómez-Pavón, Paloma González García, Inés Francés Román, Maite Vidán Astiz, José Gutiérrez Rodríguez, Gregorio Jiménez Díaz, Nuria Pilar Montero Fernández, Baldomero Álvarez Fernández, José María Jiménez Páez, Recomendaciones en la prevención de reacciones adversas a medicamentos en personas mayores con demencia, Revista Española de Geriatría y Gerontología, 2010, 45, 2, 89

    CrossRef

  16. 16
    María Jesús González Moneo, Utilidad de los fármacos en la demencia, FMC - Formación Médica Continuada en Atención Primaria, 2010, 17, 5, 326

    CrossRef

  17. 17
    David T. Nash, Cholesterol, lipoproteins, and cognitive impairment, Journal of Clinical Lipidology, 2009, 3, 6, 368

    CrossRef

  18. 18
    Joseph Quinn, Primary Prevention of Dementia,
  19. 19
    Research, Developments and Media Coverage,
  20. 20
    Bernadette McGuinness, John O'Hare, David Craig, Roger Bullock, Reem Malouf, Peter Passmore, Statins for the treatment of dementia, The Cochrane Library,